Horizon Discovery announces collaboration with Novartis for X-MAN cell-lines

Posted on: Wed, 18 Nov 2009 14:01:00 EST


Symbols: NVS
Nov 18, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
NVS | Quote | Chart | News | PowerRating -- Horizon Discovery, Ltd., a UK-based translational genomics company, has entered into a four year collaboration with Novartis AG, a Switzerland-based pharmaceutical company.

This is the second business agreement between Horizon and Novartis and and sees the use of Horizon's proprietary GENESIS(TM) gene-engineering platform to develop a broad panel of custom generated genetically-defined human 'X-MAN' cancer models for deployment in Novartis's drug discovery research programs.

Under this collaboration, Novartis will pay an upfront, milestone and renewal fees to Horizon.

Deal Type    Partnership
Sub-Category Development
Deal Status Announced: 2009-11-17

Deal Participants

Partner 1 (Company) Horizon Discovery, Ltd.
Partner 2 (Company) Novartis AG

For full details on Novartis Ag Ads (NVS) NVS. Novartis Ag Ads (NVS) has Short Term PowerRatings at TradingMarkets. Details on Novartis Ag Ads (NVS) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.